Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Summit's Integrated Wavefront Technology To Break In 2001

This article was originally published in The Gray Sheet

Executive Summary

Summit Technology, backed by encouraging results from 20 patients treated thus far in an ongoing feasibility trial, is hoping to market a customized refractive laser surgical system integrating the company's CustomCornea wavefront measuring device with its LADARVision system by the end of 2001.

You may also be interested in...



Genzyme Surgical Is Out Of General's Shadow Following January Run-up

Wall Street began to take note in January of Genzyme Surgical Products' leading position in the minimally invasive cardiac surgery market, as the stock price of the Genzyme General spin-off jumped 74.2%. The issue closed the month at 10-1/8, up 5-3/16.

LaserSight Views Pricing Options As Key To LaserScan Marketing Plan

LaserSight is highlighting its flexible payment and pricing scheme for its firm's LaserScan LSX ophthalmic excimer laser system as the firm gears up to compete with market leader Visx, with which it withdrew from patent licensing negotiations on Feb. 1.

Genzyme Surgical Is Out Of General's Shadow Following January Run-up

Wall Street began to take note in January of Genzyme Surgical Products' leading position in the minimally invasive cardiac surgery market, as the stock price of the Genzyme General spin-off jumped 74.2%. The issue closed the month at 10-1/8, up 5-3/16.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel